PLSE (Pulse Biosciences) 5-Year EBITDA Growth Rate : 14.00% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences 5-Year EBITDA Growth Rate?

Pulse Biosciences's EBITDA per Share for the three months ended in Sep. 2024 was $-0.22.

During the past 3 years, the average EBITDA Per Share Growth Rate was 25.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pulse Biosciences was 25.10% per year. The lowest was -62.90% per year. And the median was -4.35% per year.

Competitive Comparison of Pulse Biosciences's 5-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulse Biosciences's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's 5-Year EBITDA Growth Rate falls into.

Pulse Biosciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Pulse Biosciences (NAS:PLSE) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Pulse Biosciences 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulse Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

6L8:Germany

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Executives

Robert W Duggan	director, 10 percent owner	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy	officer: Chief Commercial Officer	50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner	officer: CFO & EVP Admin. and Finance	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray	director	C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono	director
Ed Ebbers	officer: EVP & GM, Dermatology	3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D	director	C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg	director	12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow	officer: CFO & SVP Admin. and Finance	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588